Primecap Management
AMLX icon

Primecap Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Primecap Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$28.4K – 333
2024
Q1 		$28.4K Sell
10,000
-146,900
-94% -$1.92M ﹤0.01% 335
2023
Q4 		$2.31M Sell
156,900
-148,000
-49% -$2.27M ﹤0.01% 306
2023
Q3 		$5.58M Buy
+304,900
New +$6.45M ﹤0.01% 278

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Primecap Management's AMLX Position: Q2 2024 in Review

Primecap Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2024, closing a stake of 10,000 shares — an estimated $28.4K sold.

Primecap Management first reported a position in AMLX in Q3 2023 and held it in 3 quarters. The position peaked at $5.58M in Q3 2023. 119 funds tracked by Wall St. Rank hold AMLX as of Q2 2024.

  • Primecap Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Primecap Management sold 10,000 Amylyx Pharmaceuticals shares in Q2 2024, an estimated $28.4K.
  • Primecap Management first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Primecap Management's Amylyx Pharmaceuticals position peaked at $5.58M in Q3 2023.
  • 119 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2024.

Based on Primecap Management's 13F filing for Q2 2024, filed 9 Aug 2024.